To read the full story
Related Article
- Subcutaneous Entyvio Wins US FDA Nod for Crohn’s Disease: Takeda
April 22, 2024
- Entyvio Subcutaneous Form Approved in US: Takeda
September 29, 2023
- FDA Accepts BLA Re-Submission for Takeda’s Entyvio SC
May 1, 2023
- US Launch of Takeda’s Entyvio SC to Be Pushed Back to 2022
September 4, 2020
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Entyvio’s SC Form Accepted by US FDA for Review: Takeda
May 13, 2019
BUSINESS
- Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Leqembi Sustains Benefits in Early Alzheimer’s after 5 Years of Treatment
November 18, 2026
- Meiji Invests US$50 Million in Arcturus to Expand mRNA Collaboration
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





